IINN: Utang kumulatif perusahaan Inspira Technologies Oxy B.H.N. Ltd

Inspira Technologies Oxy has optimized production through partnerships with CDMO vendors, ensuring strict quality control. Company management is striving for a technological breakthrough in the creation of artificial lungs. The total amount of borrowed funds in the GURU.Markets terminal reflects the dynamics of liabilities, where 0.00 serves as the current metric level. The business's competitiveness is based on patents for non-invasive blood oxygenation, which minimize patient risks.

Developing innovative blood oxygenation systems to challenge the ventilator monopoly requires significant R&D capital expenditures and FDA certification. Analyzing the financial obligations chart, the investor assesses the total volume of external loans, where debt dynamics serve as an indicator of the balance between long-term growth and the risk of insolvency during the technological race for Inspira Technologies Oxy (IINN).